Correction: Editorial Review: Progress in the Management of Meningiomas

Overview

This correction addresses an error in the editorial regarding meningioma management, specifically the removal of unrelated research content.

Background

Meningiomas are the most common primary brain tumors, accounting for nearly 40% of intracranial tumors. The management of these tumors is evolving.

Data Highlights

No numerical or trial data presented in the article.

Key Findings

• The editorial has been corrected to remove unrelated research content.
• Advanced computational techniques are critical in developing treatment strategies for meningiomas.
• Deep learning and transformer-based models offer improved context-aware recognition in medical texts.
• Incorporating advanced models into biomedical pipelines could improve individualized meningioma care.
• Continued evolution in diagnostic and treatment paradigms is essential for effective meningioma management.

Clinical Implications

The correction highlights the need for accurate representation of research in clinical discussions.

Conclusion

The editorial correction emphasizes the importance of clarity in medical literature.

Related Resources & Content

1. Lichtor, T., Frontiers in Neurology, 2026 -- Correction: Editorial Review: Progress in the Management of Meningiomas
2. Journal of Neuro-Oncology — Surgical Approaches to Intracranial Meningiomas in the Context of Molecular Advances
3. Journal of Neuro-Oncology — Novel Systemic Therapies for Meningioma Management
4. European Radiology — ESR Bridges: A Multidisciplinary Approach to Imaging and Treatment of Brain Tumors
5. Frontiers in Oncology — Editorial: Innovative strategies in overcoming glioblastoma: advancements in treatment and research
6. Surgical Approaches to Intracranial Meningiomas in the Context of Molecular Advances
7. Novel Systemic Therapies for Meningioma Management
8. ESR Bridges: A Multidisciplinary Approach to Imaging and Treatment of Brain Tumors
9. cIMPACT-NOW update 8: Clarifications on molecular risk parameters and recommendations for WHO grading of meningiomas
10. EORTC Clinical Trial 1308
11. Abemaciclib in meningiomas with somatic NF2 or CDK pathway alterations: the phase 2 Alliance A071401 trial - PubMed